Senior Manager, Financial Reporting at Acadia Pharmaceuticals

Waltham, Massachusetts, United States

Acadia Pharmaceuticals Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, PharmaceuticalIndustries

Requirements

  • Bachelor’s degree in accounting or related field; CPA designation strongly preferred
  • 7+ years of experience in public accounting and/or SEC reporting and consolidations in a public company (Mix of Big 4 and industry experience preferred)
  • Experience with NetSuite and SEC reporting platform Workiva a plus
  • Experience with CPM tools (e.g. OneStream, DataRails, Hyperion)
  • Strong understanding of US GAAP, SEC regulations, and financial reporting requirements
  • Excellent analytical and problem-solving skills
  • Effective communication and collaboration skills with the ability to interact with cross-functional teams and external stakeholders
  • Ability to provide clear explanations of accounting matters to team members of all levels
  • Self-motivated

Responsibilities

  • Prepare reporting packages for financial statements and internal reporting
  • Assist in the preparation and filing of quarterly and annual reports on Forms 10-Q and 10-K, respectively, in accordance with SEC regulations
  • Prepare the consolidated cash flow statement
  • Lead the monthly and quarterly consolidation tasks of Madrigal’s 10+ legal entities (multi-currency), including preparing and managing top-side journal entries
  • Oversee global intercompany eliminations entries
  • Manage global chart of accounts and financial statement line-item mappings in DataRails
  • Ensure appropriate integration and connection of DataRails with Madrigal’s ERP systems
  • Continuously enhance the close and financial reporting processes to improve efficiency, accuracy, and internal controls
  • Contribute to the financial close, as needed, as reviewer of reconciliations or preparer of memos / workpapers for complex accounting transactions
  • Stay current on new accounting standards and SEC rules and regulations, implementing changes to reporting processes as necessary
  • Assist with the implementation of new accounting standards and miscellaneous accounting-related projects (e.g. business development and M&A projects, etc.)
  • Coordinate with internal and external auditors
  • Coach other team members on accounting matters and provide exposure to staff on areas within SEC reporting to expand the team’s skillsets

Skills

Financial Reporting
SEC Reporting
10-Q
10-K
Financial Consolidations
Cash Flow Statements
GAAP
Accounting Standards
Financial Statements

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.
Potential clinical trial delays could affect drug approval timelines.
Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.
The company has a strong R&D foundation, developing innovative small molecule drugs.
Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.
Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.
The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI